Zacks: Brokerages Anticipate Aptevo Therapeutics Inc (APVO) to Post -$0.59 EPS
Wall Street brokerages forecast that Aptevo Therapeutics Inc (NASDAQ:APVO) will report earnings of ($0.59) per share for the current quarter, according to Zacks Investment Research. Two analysts have provided estimates for Aptevo Therapeutics’ earnings. The lowest EPS estimate is ($0.60) and the highest is ($0.58). Aptevo Therapeutics posted earnings of $0.14 per share during the same quarter last year, which would indicate a negative year-over-year growth rate of 521.4%. The business is scheduled to announce its next quarterly earnings results on Thursday, November 8th.
On average, analysts expect that Aptevo Therapeutics will report full-year earnings of ($2.42) per share for the current year, with EPS estimates ranging from ($2.47) to ($2.36). For the next year, analysts expect that the business will post earnings of ($2.35) per share, with EPS estimates ranging from ($2.68) to ($2.02). Zacks Investment Research’s EPS calculations are a mean average based on a survey of analysts that that provide coverage for Aptevo Therapeutics.
Aptevo Therapeutics (NASDAQ:APVO) last released its quarterly earnings data on Thursday, August 9th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.07. Aptevo Therapeutics had a net margin of 74.01% and a negative return on equity of 45.53%. The business had revenue of $6.83 million for the quarter, compared to analyst estimates of $4.17 million.
A number of institutional investors and hedge funds have recently made changes to their positions in the business. Northern Trust Corp lifted its stake in Aptevo Therapeutics by 21.2% in the second quarter. Northern Trust Corp now owns 70,416 shares of the biotechnology company’s stock valued at $352,000 after buying an additional 12,299 shares in the last quarter. Citadel Advisors LLC lifted its stake in Aptevo Therapeutics by 215.4% in the first quarter. Citadel Advisors LLC now owns 39,653 shares of the biotechnology company’s stock valued at $130,000 after buying an additional 27,079 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. bought a new position in Aptevo Therapeutics in the second quarter valued at approximately $148,000. EAM Investors LLC bought a new position in Aptevo Therapeutics in the second quarter valued at approximately $552,000. Finally, Dimensional Fund Advisors LP lifted its stake in Aptevo Therapeutics by 11.2% in the first quarter. Dimensional Fund Advisors LP now owns 1,219,852 shares of the biotechnology company’s stock valued at $3,989,000 after buying an additional 123,236 shares in the last quarter. 33.08% of the stock is currently owned by hedge funds and other institutional investors.
Aptevo Therapeutics stock traded down $0.08 during midday trading on Friday, hitting $4.27. 500 shares of the stock were exchanged, compared to its average volume of 152,585. Aptevo Therapeutics has a 52 week low of $2.29 and a 52 week high of $6.35. The firm has a market capitalization of $115.16 million, a price-to-earnings ratio of -2.79 and a beta of 0.79. The company has a debt-to-equity ratio of 0.27, a current ratio of 3.66 and a quick ratio of 3.50.
Aptevo Therapeutics Company Profile
Aptevo Therapeutics Inc, a biotechnology company, engages in the discovery, development, commercialization, and sale of novel oncology and hematology therapeutics in the United States. Its marketed products include IXINITY, which is indicated in adults and children 12 years of age and older with hemophilia B for control and prevention of bleeding episodes, and management of bleeding during operations; and WinRho SDF for the treatment of autoimmune platelet disorders, as well as for the treatment of hemolytic disease of the newborn.
Recommended Story: What are earnings reports?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aptevo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptevo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.